Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

Trial Profile

CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nomacopan (Primary)
  • Indications Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONSERVE
  • Sponsors Akari Therapeutics
  • Most Recent Events

    • 07 Jul 2020 The trial has been Discontinued in Lithuania and UK (Global End Date: 22 Jun 2020), according to European Clinical Trials Database record.
    • 10 Jan 2020 According to a Akari Therapeutics media release, Dr Austin Kulasekararaj of King's College Hospital, London University, UK, is the lead investigator of this trial.
    • 24 Apr 2017 New trial record
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top